Sugi Predict

Sugi Predict / Targets / MERTK

MERTK

Tyrosine-protein kinase Mer · Q12866 · MERTK on Sugi Atlas →

85,196 patent compounds predicted against MERTK, 49,574 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL263234 SCHEMBL263234 0.52 12/20
SCHEMBL140985 SCHEMBL140985 0.54 11/20
SCHEMBL59020 SCHEMBL59020 0.47 10/20
SCHEMBL74518 SCHEMBL74518 0.46 10/20
SCHEMBL143451 SCHEMBL143451 0.51 9/20
SCHEMBL59352 SCHEMBL59352 0.56 7/20
SCHEMBL106402 SCHEMBL106402 0.53 7/20
Golvatinib Golvatinib (SCHEMBL93491) 0.51 7/20
SCHEMBL65796 SCHEMBL65796 0.50 7/20
SCHEMBL105748 SCHEMBL105748 0.49 7/20
SCHEMBL139114 SCHEMBL139114 0.54 6/20
SCHEMBL139145 SCHEMBL139145 0.54 6/20
SCHEMBL60066 SCHEMBL60066 0.46 6/20
SCHEMBL58193 SCHEMBL58193 0.41 6/20
SCHEMBL138396 SCHEMBL138396 0.51 5/20
SCHEMBL58529 SCHEMBL58529 0.51 5/20
SCHEMBL59234 SCHEMBL59234 0.49 5/20
SCHEMBL143639 SCHEMBL143639 0.49 5/20
SCHEMBL143640 SCHEMBL143640 0.49 5/20
SCHEMBL143778 SCHEMBL143778 0.49 5/20

Clinical trials — most relevant to MERTK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study PHASE2/PHASE3COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer PHASE2UNKNOWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma PHASE2COMPLETED
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy PHASE2WITHDRAWN
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor PHASE2COMPLETED
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma PHASE2COMPLETED
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) PHASE2RECRUITING
Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC PHASE2NOT_YET_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies PHASE1COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer PHASE1COMPLETED
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria PHASE1COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease nanCOMPLETED
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis nanACTIVE_NOT_RECRUITING
Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer nanUNKNOWN
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a MERTK binder may also engage these)

ProteinNameSimilarity
P57097 — 1.000 P57097 →
Q60805 — 1.000 Q60805 →
Q98949 — 0.991 Q98949 →
Q8BR86 — 0.990 Q8BR86 →
Q8IZU9 — 0.989 Q8IZU9 →
A0JM20 — 0.988 A0JM20 →
Q8QFP9 — 0.984 Q8QFP9 →
P55146 — 0.982 P55146 →
Q58EG3 — 0.979 Q58EG3 →
Q32MD9 — 0.978 Q32MD9 →
Q9YI66 — 0.978 Q9YI66 →
Q90330 — 0.978 Q90330 →
P55144 — 0.978 P55144 →
Q9I8X3 — 0.977 Q9I8X3 →
Q4KMG0 — 0.976 Q4KMG0 →
Q04589 — 0.976 Q04589 →
Q9Z138 — 0.976 Q9Z138 →
P18460 — 0.976 P18460 →
AXL Tyrosine-protein kinase receptor UFO 0.976 landscape →
Q98936 — 0.976 Q98936 →
P18461 — 0.976 P18461 →
O35158 — 0.975 O35158 →
Q498D6 — 0.975 Q498D6 →
FGFR3 Fibroblast growth factor receptor 3 0.975 landscape →
P21803 — 0.975 P21803 →
Q03142 — 0.975 Q03142 →
Q52KR2 — 0.975 Q52KR2 →
Q00560 — 0.975 Q00560 →
Q86TH1 — 0.974 Q86TH1 →
Q80ZD8 — 0.974 Q80ZD8 →